

Your inside look into the world of research at SFH

Happy New Year!

Welcome to a Winter edition of The Research Snapshot.

As we enter the final quarter of 2021-22 we are optimistic about the future of Research at SFH and excited to welcome new members of our growing team





In May 2021 we commenced this study at our site. We are recruiting to tier 1 (data collection). The study looks at how different patients recover from COVID-19 and aims to identify where there are longer-term health problems for those that were hospitalised with the virus.

Key questions the study is looking to answer are:

- Why some patients suffer more severely from the disease
- Why some people recover quicker
- Treatments that may have benefitted patients whilst they were in hospital
- How we can improve care of patients once they are discharged

The table below shows the other tiers that are being run at other sites.



PREVeNT RA

PRE-clinical Evaluation of
Novel Targets in RA

The Rheumatology Research portfolio is currently recruiting to the Prevent RA study, run by Manchester University.

The PREVENT RA (Rheumatoid Arthritis) study is interested in how our genes, environment and other factors lead to some people developing RA whilst other people do not.

The study aims to understand risk factors for developing RA. This is being done by studying individuals who are currently well but who are first degree relatives (i.e. is a parent, child, brother or sister) of someone with RA.

The study will examine a number of factors for each person - including their genes, the immune system and their lifestyle or environment to understand what makes people more likely or less likely to develop RA.

It is hoped the study will help to develop interventions for preventing the condition, which we then aim to test in future randomised studies.

If the study is of interest to you or you would like further information you can call 0161 275 5504 or look online at www.preventra.net.

Ethics Approval was given for additional trial treatment for the Recovery trial to which we started recruiting in early 2020. The treatment arms are:

- High-dose Corticosteroids
- Sorovimab
- Empagliflozin
- Standard Care



WELCOME

Follow us on Twitter
@SFHresearch



We are the newest members of the Research and Innovation Team. Our names are Jill and Kaytie.

Originally we were interested in Research in our clinical areas, starting out as Research Champions.

This gave us an insight into clinical trials in our area, and access to additional training.

We were then given the opportunity to work within the Research department as members of the Research Academy. This involved screening, recruiting and collecting data for trials within the trust, giving us a better insight into the role of the Research Nurse.

The knowledge and skills we gained during our time on the Academy enabled us to highlight potential patients for trials in our area.

The research and Innovation department is developing and expanding and we have been lucky to receive permanent posts with the team. We are extremely grateful for all the support and opportunities given to us by the team and are excited for our future in research.



Working as part of the Research team our role as a Healthcare Assistants are varied.

As we offer clinical and non-clinical support to all the Research team, everyday can be different, depending on which Specialist Nurse we are supporting. This makes our role very unique as we get to help patients in all areas of the hospital.

An enjoyable part of our role is meeting a wide range of people from patients and members of staff across the trust. We have been made to feel very welcome by the whole team and look forward to supporting them in promoting Research and innovation. It is great to see a study we have been working on become part of standard care for COVID-19 patients.

We will be continually developing as members the Research team.

THANK YOU!

We would like to say thank you to all the Consultants, Ward Staff and support departments across the trust for your help and commitment as we work together on the new arms of the RECOVERY trial and the rebuilding of our portfolio

